Kaleido Biosciences Raises $101 Million to Develop Microbiome Therapies
- Posted by ISPE Boston
- On June 28, 2018
Bedford-based Kaleido Biosciences, a clinical-stage healthcare company developing novel chemistries to drive functions of the microbiome organ, has raised $101 million in an oversubscribed Series C financing. Kaleido plans to use the proceeds from this financing to advance its pipeline, including conducting multiple clinical studies across several therapeutic areas, and to expand its platform. “We […]
Read More